Features Partner Sites Information LinkXpress
Sign In
Demo Company

Blocking Cell Movement Explored to Stop the Spread of Cancer

By BiotechDaily International staff writers
Posted on 14 Jul 2014
Print article
Image: Migrating embryonic neural crest cells (Photo courtesy of UCL - University College London).
Image: Migrating embryonic neural crest cells (Photo courtesy of UCL - University College London).
Learning more about how cells travel through the body could lead to innovative new treatments to block cancer cells from metastasizing and causing secondary tumors, according to new research.

Scientists discovered that cells can change into an invasive, liquid-like state to readily move through the thin channels in the human body. This transformation is activated by chemical signals, which could be blocked to stop cancer cells from spreading. Most cancer deaths are not caused by to primary tumors, but to secondary tumors in major organs, such as the lungs or brain, caused by cells moving from the original tumor to other places in the body.

The study led by the University College London (UCL; UK) researchers and published July 8, 2014, in the Journal of Cell Biology, used embryonic cells to better determine how groups of cells move in a developmental process similar to that exploited by cancer to spread around the body. The scientists reported that a molecule called lysophosphatidic acid (LPA) transforms cells from a solid-like to a liquid-like state, allowing cells to flow between normal tissues in the body. They were able to turn off the signals from LPA, stopping the cells from moving down the narrow, blood vessel-like channels.

Lead scientist Prof. Roberto Mayor, from the UCL department of cell and developmental biology, said, “We have found a way to stop the movement of embryonic cells by blocking LPA signals. It is likely that a similar mechanism operates during cancer invasion, which suggests a possible alternative which cancer treatments might work in the future, if therapies can be targeted to limit the tissue fluidity of tumors. Our findings are important for the fields of cell, developmental and cancer biology. Previously, we thought cells only moved around the body either individually or as groups of well-connected cells. What we have discovered is a hybrid state where cells loosen their links to neighboring cells but still move en masse together, like a liquid. Moreover, we can stop this movement.”

Related Links:

University College London

Print article



view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more

Lab Technologies

view channel
Image: The new ambr 15 fermentation micro-bioreactor system was designed to enhance microbial strain screening applications (Photo courtesy of Sartorius Stedim Biotech).

New Bioreactor System Streamlines Strain Screening and Culture

Biotechnology laboratories working with bacterial cultures will benefit from a new automated micro bioreactor system that was designed to enhance microbial strain screening processes. The Sartorius... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.